These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22449628)

  • 1. Treatment of hypereosinophilic syndromes--the first 100 years.
    Butterfield JH; Weiler CR
    Semin Hematol; 2012 Apr; 49(2):182-91. PubMed ID: 22449628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapies for hypereosinophilic syndromes.
    Antoniu SA
    Neth J Med; 2010 Aug; 68(1):304-10. PubMed ID: 20739727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical management of the hypereosinophilic syndromes.
    Cogan E; Roufosse F
    Expert Rev Hematol; 2012 Jun; 5(3):275-89; quiz 290. PubMed ID: 22780208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
    Ogbogu PU; Bochner BS; Butterfield JH; Gleich GJ; Huss-Marp J; Kahn JE; Leiferman KM; Nutman TB; Pfab F; Ring J; Rothenberg ME; Roufosse F; Sajous MH; Sheikh J; Simon D; Simon HU; Stein ML; Wardlaw A; Weller PF; Klion AD
    J Allergy Clin Immunol; 2009 Dec; 124(6):1319-25.e3. PubMed ID: 19910029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
    Mehr S; Rego S; Kakakios A; Kilham H; Kemp A
    J Pediatr; 2009 Aug; 155(2):289-91. PubMed ID: 19619754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis.
    Williams AK; Dou C; Chen LYC
    Br J Haematol; 2021 Dec; 195(5):669-680. PubMed ID: 34105142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants.
    Roufosse F; Goldman M; Cogan E
    Semin Respir Crit Care Med; 2006 Apr; 27(2):158-70. PubMed ID: 16612767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
    Schwartz LB; Sheikh J; Singh A
    Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report.
    Tan D; Hwang W; Ng HJ; Goh YT; Tan P
    Int J Hematol; 2004 Jul; 80(1):75-7. PubMed ID: 15293573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hypereosinophilic syndrome--recent developments in diagnosis and treatment].
    Hellmich B; Holl-Ulrich K; Gross WL
    Dtsch Med Wochenschr; 2007 Sep; 132(37):1892-6. PubMed ID: 17823882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Disorders with eosinophilia, treatment of hypereosinophilic syndrome].
    Borbényi Z
    Orv Hetil; 2005 May; 146(18 Suppl 1):911-6. PubMed ID: 15921304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome.
    Butterfield JH
    Leuk Res; 2009 Aug; 33(8):1127-9. PubMed ID: 19144405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel approaches to therapy of hypereosinophilic syndromes.
    Simon HU; Cools J
    Immunol Allergy Clin North Am; 2007 Aug; 27(3):519-27. PubMed ID: 17868862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib.
    Koury MJ; Newman JH; Murray JJ
    Am J Med; 2003 Nov; 115(7):587-9. PubMed ID: 14599646
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-IL-5 and hypereosinophilic syndromes.
    Sutton SA; Assa'ad AH; Rothenberg ME
    Clin Immunol; 2005 Apr; 115(1):51-60. PubMed ID: 15870021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.
    Ault P; Cortes J; Koller C; Kaled ES; Kantarjian H
    Leuk Res; 2002 Sep; 26(9):881-4. PubMed ID: 12127565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and therapeutic management in patients with hypereosinophilic syndromes.
    Helbig G; Kyrcz-Krzemień S
    Pol Arch Med Wewn; 2011; 121(1-2):44-52. PubMed ID: 21346698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].
    Menif S; Ben Romdhane N; Hafsia R
    Rev Med Interne; 2008 Jan; 29(1):65-7. PubMed ID: 18036706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia.
    Kalac M; Quintás-Cardama A; Vrhovac R; Kantarjian H; Verstovsek S
    Cancer; 2007 Sep; 110(5):955-64. PubMed ID: 17654661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypereosinophilic syndromes in the precision medicine era: clinical, molecular aspects and therapeutic approaches (targeted therapies).
    Iurlo A; Cattaneo D; Gianelli U
    Expert Rev Hematol; 2019 Dec; 12(12):1077-1088. PubMed ID: 31588817
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.